HomepageNBIX • NASDAQ
add
Neurocrine Biosciences
Vorige slotkoers
$Â 117,52
Dag-range
$Â 115,66 - $Â 119,67
Jaar-range
$Â 84,23 - $Â 157,98
Beurswaarde
11,45Â mld. USD
Gem. volume
1,85Â mln.
Koers/winst
39,22
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 572,60Â mln. | 11,12% |
Bedrijfskosten | 276,50Â mln. | 13,74% |
Netto inkomsten | 7,90Â mln. | -81,80% |
Netto winstmarge | 1,38 | -83,61% |
Winst per aandeel | 0,70 | -41,67% |
EBITDA | 31,30Â mln. | -71,93% |
Effectief belastingtarief | 46,26% | — |
Balans
Totale activa
Totale passiva
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 943,50Â mln. | -22,06% |
Totale activa | 3,69Â mld. | 6,20% |
Totale passiva | 1,15Â mld. | 6,05% |
Totaal aandelenvermogen | 2,54 mld. | — |
Uitstaande aandelen | 98,97 mln. | — |
Koers-boekwaardeverhouding | 4,59 | — |
Rendement op activa | 1,60% | — |
Rendement op kapitaal | 1,94% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | mrt 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 7,90Â mln. | -81,80% |
Operationele kasstroom | 64,80Â mln. | -50,27% |
Kasstroom uit beleggingen | 14,20Â mln. | 125,82% |
Kasstroom uit financiering | -117,90Â mln. | -268,67% |
Nettomutatie in liquide middelen | -38,90Â mln. | -126,79% |
Vrije kasstroom | 28,91Â mln. | -88,50% |
Over
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Opgericht
1992
Hoofdvestiging
Website
Werknemers
1.800
